Hua Medicine - ESG Rating & Company Profile powered by AI
This report of Hua Medicine employs information from across the web as well as from available disclosures by Hua Medicine. This article contains a Q&A table for Hua Medicine. Alternative companies in the scoring peer group for Hua Medicine are displayed.
Hua Medicine in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 3.9; made up of an environmental score of 2.0, social score of 8.0 and governance score of 1.6.
3.9
Low ImpactEnvironmental
Social
Governance

Peer Group Comparison
Rank | Company | SDG Transparency Score ⓘ | Performance |
---|---|---|---|
1 | Caladrius Biosciences Inc | 8.0 | High |
1 | Can Fite Biopharma Ltd | 8.0 | High |
1004 | Xeris Pharmaceuticals Inc | 4.0 | High |
1004 | Xenon Pharmaceuticals Inc | 4.0 | High |
... | ... | ... | |
1089 | Hua Medicine | 3.9 | Medium |
1089 | Aclaris Therapeutics Inc | 3.9 | Medium |
1089 | Allogene Therapeutics Inc | 3.9 | Medium |
... | ... | ... | |
1970 | Zyden Gentec Ltd | 0.0 | Low |
1970 | iNtRON Biotechnology Inc | 0.0 | Low |
... | ... | ... |

Frequently Asked Questions
Does Hua Medicine have an accelerator or VC vehicle to help deliver innovation?
Does Hua Medicine disclose current and historical energy intensity?
Does Hua Medicine report the average age of the workforce?
Does Hua Medicine reference operational or capital allocation in relation to climate change?
Does Hua Medicine disclose its ethnicity pay gap?
Does Hua Medicine disclose cybersecurity risks?
Does Hua Medicine offer flexible work?
Does Hua Medicine have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Does Hua Medicine disclose the number of employees in R&D functions?
Does Hua Medicine conduct supply chain audits?
Does Hua Medicine disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Is there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Does Hua Medicine conduct 360 degree staff reviews?
Does Hua Medicine disclose the individual responsible for D&I?
Does Hua Medicine disclose current and historical air emissions?
Is there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Is executive remuneration linked to climate performance?
Does the Board describe its role in the oversight of climate-related risks and opportunities?
Does Hua Medicine disclose current and / or historical scope 2 emissions?
Does Hua Medicine disclose water use targets?
Does Hua Medicine have careers partnerships with academic institutions?
Did Hua Medicine have a product recall in the last two years?
Does Hua Medicine disclose incidents of discrimination?
Does Hua Medicine allow for Work Councils/Collective Agreements to be formed?
Has Hua Medicine issued a profit warning in the past 24 months?
Does Hua Medicine disclose parental leave metrics?
Does Hua Medicine disclose climate scenario or pathway analysis?
Does Hua Medicine disclose current and / or historical scope 1 emissions?
Are Operating Expesnses linked to emissions reduction?
Does Hua Medicine disclose the pay ratio of women to men?
Does Hua Medicine support suppliers with sustainability related research and development?
Does Hua Medicine disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Does Hua Medicine reflect climate-related risks in its financial statements?
Is there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Is Hua Medicine involved in embryonic stem cell research?
Does Hua Medicine disclose GHG and Air Emissions intensity?
Does Hua Medicine disclose its waste policy?
Does Hua Medicine report according to TCFD requirements?
Does Hua Medicine disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Does Hua Medicine disclose energy use targets?
Does Hua Medicine disclose its Renewable Energy targets?

Are emissions metrics verified by STBi?

Does Hua Medicine have a policy relating to cyber security?
Have a different question?
Potential Risks for Hua Medicine
These potential risks are based on the size, segment and geographies of the company.
Hua Medicine (Shanghai) Ltd. operates as a clinical-stage drug development company that focuses on therapies for the treatment of diabetes in China. It develops Dorzagliatin or HMS5552, an oral drug for the treatment of Type 2 Diabetes (T2D); and Dorzagliatin in combination with Metformin, Sitagliptin, and Empagliflozin that is in Phase I clinical trial for treatment of T2D. The company also offers Dorzagliatin in combination with Pioglitazone for NASH; in combination with GLP-1 for Alzheimer diseases; and in combination with late stage T2D and Type 1 Diabetes. In addition, it is developing mGLUR5 for the treatment of Parkinson's disease levodopa-induced dyskinesia. The company was incorporated in 2011 and is based in Beijing, China.